Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Gains from Investment Securities (2024 - 2025)

Historic Gains from Investment Securities for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $15.5 million.

  • Prelude Therapeutics' Gains from Investment Securities rose 41641563.68% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $15.5 million, marking a year-over-year increase of 41641563.68%. This contributed to the annual value of $14.2 million for FY2024, which is 64216.91% up from last year.
  • As of Q3 2025, Prelude Therapeutics' Gains from Investment Securities stood at $15.5 million, which was up 41641563.68% from $16.5 million recorded in Q2 2025.
  • Prelude Therapeutics' Gains from Investment Securities' 5-year high stood at $16.5 million during Q2 2025, with a 5-year trough of -$458000.0 in Q1 2024.